Core Insights - A new rapid antidepressant strategy has been proposed by a collaborative team from Hefei Comprehensive National Science Center and other institutions, leading to the development of a candidate compound TMU4142, which shows significant rapid antidepressant effects in animal tests without notable side effects, providing a new approach for the development of next-generation rapid antidepressants [1][3] Group 1: Antidepressant Research - Depression is a major global mental health burden affecting over 300 million people, with existing mainstream antidepressants like SSRIs having significant drawbacks, including delayed onset of effects [1] - The delay in drug efficacy is attributed to the negative feedback inhibition effect of serotonin 1A autoreceptors in the dorsal raphe nucleus, which suppress serotonin release, leading to a lag in therapeutic effects [2] Group 2: Mechanism and Development - The research team identified that serotonin 1A receptors in different brain regions preferentially couple with different G proteins, which can be leveraged to design a compound that selectively activates the GoA protein while minimizing activation of the Gi3 protein, thus avoiding the negative feedback effect [2] - The candidate compound TMU4142 was optimized from the reference molecule Pindolol, demonstrating improvement in depressive states in mice within one hour of injection, and it does not trigger the negative feedback mechanism at therapeutic doses [3] Group 3: Future Directions - The research team plans to continue optimizing the compound and conduct systematic preclinical studies, aiming to advance TMU4142 into clinical trials to provide new hope for patients with depression [3]

Core Viewpoint - The article discusses the rising prevalence of depression and introduces a new rapid antidepressant strategy based on selective activation of the 5-HT 1A receptor, which addresses the slow onset of traditional SSRIs [3][6][12]. Group 1: Background on Depression and SSRIs - Depression has become a leading cause of disability globally, surpassing cardiovascular diseases and cancer [3]. - The monoamine hypothesis, proposed in the 1950s, links depression to a deficiency of monoamine neurotransmitters, leading to the development of various antidepressants [3]. - SSRIs are the latest generation of antidepressants that increase serotonin levels in the brain but often take weeks to show effects and can have side effects [3][6]. Group 2: New Research Findings - A research team published a study in the journal Cell, proposing a pathway-selective 5-HT 1A receptor agonist as a rapid antidepressant strategy [5]. - The study introduces TMU4142, a candidate agonist that shows significant rapid antidepressant effects in mouse models [6][8]. - The research characterizes the G i/o signaling features of the 5-HT 1A receptor and identifies the structural interactions with various agonists and G i/o family proteins [8][10]. Group 3: Mechanism and Implications - TMU4142 selectively activates G oA while minimizing G i3 activation, leading to rapid antidepressant effects without activating the 5-HT 1A receptor in the dorsal raphe nucleus [10][12]. - The findings suggest that distinguishing between downstream G i/o signaling pathways of heteroreceptors and autoreceptors could be a promising strategy for developing fast-acting antidepressants [12].